U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07063043) titled 'Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases' on July 03.
Brief Summary: FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET/CMR provides comprehensive cardiac assessment without extra radiation. This advanced imaging approach improves diagnosis and personalized treatment for better patient outcomes.
Study Start Date: Dec. 01, 2024
Study Type: OBSERVATIONAL
Condition:
Cardiovascular Diseases (CVD)
Recruitment Status: RECRUITING
Sponsor: Shanghai East Hospital
Disclaimer: Curated by HT Syndication....